Irritable Bowel Syndrome - A potentially profitable market with limited competition

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-06-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.


Scope

  • Epidemiology and patient segmentation in irritable bowel syndrome (IBS), including a breakdown of the patient population by gender and symptom type
  • Discussion of issues with regards to IBS patient presentation, referral patterns and diagnosis such as the new Rome III diagnostic criteria
  • Overview of the current treatment controversies and unmet needs, including the market withdrawal of Novartis' Zelnorm (tegaserod)
  • Analysis of clinical trial design in the R&D drug pipeline for new IBS drug therapies in 2007


    • Report Highlights
    Despite the substantial impact IBS can have on sufferers' well being, about 7080% of sufferers have not been formerly diagnosed. Although many patients will have seen a doctor or nurse for their symptoms, they remain undiagnosed and may have visited a healthcare professional on several occasions before being formally diagnosed with IBS.

    Physicians frequently do not recognize IBS as a 'distinct' disease. Continuing physician education is needed to change this attitude and improve diagnosis, particularly in the primary care setting. A simple and easily accessible diagnostic tool adapted specifically for non-specialists and clear peer reviewed treatment guidelines are needed.

    The pipeline can be described as relatively innovative. The serotinergic class accounts for a third of candidates, however, the poor safety record and market withdrawal of Lotronex (alosetron) and Zelnorm has cast doubts over the potential of this class. FDA non-approval of cilansetron is another setback for the serotinergics.


    Reasons to Purchase

  • Quantify the key target segments of the IBS patient population across the seven major markets
  • Gain insight into opinion leaders' thoughts on the major opportunities and challenges facing the IBS market
  • Learn about key late-stage pipeline drugs and issues surrounding diagnosis and clinical trial design

    • Table of Contents

    Other users found this report page using the following search terms: ibs irritable bowle bowel irritable market ibs syndrome bowle disease presentation 060 ym

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.